News Release - Eli Lilly and Company
INDIANAPOLIS, Aug. 27, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced Zepbound ® (tirzepatide) 2.5 mg and 5 mg single-dose vials are available for self …
FDA Approves Lilly's Zepbound™ (tirzepatide ... - Eli Lilly and …
INDIANAPOLIS, Nov. 8, 2023 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company's (NYSE: LLY) Zepbound™ (tirzepatide) injection, the first and …
FDA approves Zepbound® (tirzepatide) as the first and only …
INDIANAPOLIS, Dec. 20, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound ® (tirzepatide) …
News Release - Eli Lilly and Company
Dec 5, 2023 · Lilly continues to invest in the expansion of its global manufacturing footprint to address the expected demand for innovative new treatments, like Zepbound, and help ensure …
Lilly Update on Mounjaro® and Zepbound ... - Eli Lilly and Company
May 14, 2024 · Lilly has discovered products claiming to be compounded tirzepatide medicines that contain bacteria, high impurity levels, different chemical structures, and different colors …
News Release - Eli Lilly and Company
INDIANAPOLIS, Aug. 1, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today positive topline results from the SUMMIT phase 3 clinical trial evaluating the safety and …
News Release - Eli Lilly and Company
Jun 20, 2024 · Lilly has identified fake or counterfeit products that are advertised or designed to look like Lilly’s genuine FDA-approved Mounjaro ® and Zepbound ® These products are often …
Lilly reports Q3 2024 financial results highlighted by strong …
Oct 30, 2024 · Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro and Zepbound, partially offset by $1.42 billion of revenue in Q3 2023 from the sale of rights for the …
News Release - Eli Lilly and Company
Dec 11, 2023 · Lilly's Zepbound™ (tirzepatide) achieved additional 6.7% weight loss following a 36-week open-label lead-in period, for a total mean weight loss of 26.0% from study entry over …
News Release - Eli Lilly and Company
INDIANAPOLIS, April 17, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results of the SURMOUNT-OSA phase 3 clinical trials that showed …